Weston Eriksen posted an update 4 months, 1 week ago
Gene expressions in sophisticated glycation end solution (AGE)-exposed fibroblasts by way ofGene expressions in sophisticated glycation finish solution (AGE)-exposed fibroblasts via mineralocorticoid receptor antagonistic activity. Biochem. Biophys. Res. Commun. vol. 396, no. 2, pp. 566-570, Could. 2010.  R. Berkels, R. Roesen, H. Bartels, S. PurolSchnabel, I. Kirmiziguel, H. Farmer, G.V. Born, W. Klaus, “Nisoldipine increases the bioavailability of endothelial NO” Naunyn Schmiedebergs Arch Pharmacol. vol. 364, no. two, pp. 110-116, Aug. 2001.  R. Berkels, D. Taubert, A. Rosenkranz, R. R en, “Vascular protective effects of dihydropyridine calcium antagonists. Involvement of endothelial nitric oxide” Pharmacology vol. 69, no. four, pp. 171-176, Dec. 2003.  S. Dhein, A. Salameh, R. Berkels, W. Klaus, “Dual mode of action of dihydropyridine calcium antagonists: a role for nitric oxide. Drugs vol. 58, no. 3, pp. 397-404, Sep. 1999.  H.S. Leung, X. Yao, F.P. Leung, W.H. Ko, Z.Y. Chen, M. Gollasch, Y. Huang, “Cilnidipine, a slowacting Ca2+ channel blocker, induces relaxation in porcine coronary artery: role of endothelial nitric oxide and [Ca2+]i. Br. J. Pharmacol. vol. 147, no. 1, pp. 55-63, Jan. 2006.  J. Ma, S. Kishida, G.Q. Wang, K. Meguro, H. Imuta, H. Oonuma, H. Iida, T. Jo, H. Takano, T. Morita, R. Nagai, T. Nakajima, “Comparative effects of azelnidipine along with other Ca2+-channel blockers on theinduction of inducible nitric oxide synthase in vascular smooth muscle cells. J. Cardiovasc. Pharmacol. vol. 47, no. two, pp. 314-321, Feb. 2006.  M. Matsubara, K. Yao, K. Hasegawa, “Benidipine, a dihydropyridine-calcium jir.2011.0094 channel blocker, inhibits lysophosphatidylcholine-induced fpsyg.2015.00360 endothelial injury by way of stimulation of nitric oxide release. Pharmacol. Res. vol. 53, no. 1, pp. 35-43, Jan. 2006.  M. Matsubara, O. Akizuki, J. Ikeda, K. Saeki, K. Yao, K. Sasaki, “Benidipine, an antihypertensive drug, inhibits reactive oxygen species production in polymorphonuclear leukocytes and oxidative pressure in salt-loaded stroke-prone spontaneously hypertensive rats. Eur. J Pharmacol. vol. 580, no. 1-2, pp. 201-213, Feb. 2008.  C. Rosenkranz, T. Lob, T. Breitenbach, R. Berkels, R. Roesen, “Endothelial antioxidant actions of dihydropyridines and angiotensin converting enzyme inhibitors. Eur. J. Pharmacol. vol. 529, no. 1-3, pp. 55-62, Jan. 2006.  X.P. Zhang, K.E. Loke, S. Mital, S. Chahwala, T.H. Hintze, “Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R+ enantiomer of amlodipine” J. Cardiovasc. Pharmacol. vol. 39, no. 2, pp.208-214, Feb. 2002.  JC Liang, JL Yeh, C.S. Wang, S.F. Liou, C.H. Tsai, I.J. Chen “The new generation dihydropyridine type calcium blockers, bearing 4-phenyl oxypropanolamine, show alpha-/beta-adrenoceptor antagonist and long-acting antihypertensive activities” Bioorg. Med. Chem. vol. 10, no. three, pp. 719-730, Mar. 2002.  J.L.Yeh, S.F. Liou, J.C. Liang, C.H. Lee, C.C. Chiu, Y.T. Lin, I.J. Chen, “AZD0865 site Labedipinedilol-C: a third-generation dihydropyridine-type calcium channel antagonist displaying K+ channel opening, NO-dependent and adrenergic antagonist activities” J. Cardiovasc. Pharmacol. vol. 46, no. two, pp. 130-140, Aug. 2005.  Visentin S, Rolando B, Di Stilo A, Fruttero R, Novara M, Carbone E, Roussel C, Vanthuyne N, Gasco A.